These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28208102)

  • 1. Oncogenic growth factor signaling mediating tumor escape from cellular immunity.
    Concha-Benavente F; Ferris RL
    Curr Opin Immunol; 2017 Apr; 45():52-59. PubMed ID: 28208102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy.
    Concha-Benavente F; Ferris RL
    Front Pharmacol; 2017; 8():332. PubMed ID: 28611673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
    Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
    Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
    Stewart TJ; Smyth MJ
    Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune evasion in cancer: Mechanistic basis and therapeutic strategies.
    Vinay DS; Ryan EP; Pawelec G; Talib WH; Stagg J; Elkord E; Lichtor T; Decker WK; Whelan RL; Kumara HMCS; Signori E; Honoki K; Georgakilas AG; Amin A; Helferich WG; Boosani CS; Guha G; Ciriolo MR; Chen S; Mohammed SI; Azmi AS; Keith WN; Bilsland A; Bhakta D; Halicka D; Fujii H; Aquilano K; Ashraf SS; Nowsheen S; Yang X; Choi BK; Kwon BS
    Semin Cancer Biol; 2015 Dec; 35 Suppl():S185-S198. PubMed ID: 25818339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular bases of cancer immunology].
    Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
    Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
    Waight JD; Gombos RB; Wilson NS
    Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The two sides of HER2/neu: immune escape versus surveillance.
    Seliger B; Kiessling R
    Trends Mol Med; 2013 Nov; 19(11):677-84. PubMed ID: 24035606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncology meets immunology: the cancer-immunity cycle.
    Chen DS; Mellman I
    Immunity; 2013 Jul; 39(1):1-10. PubMed ID: 23890059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse immunoediting: When immunity is edited by antigen.
    Merlo A; Dalla Santa S; Dolcetti R; Zanovello P; Rosato A
    Immunol Lett; 2016 Jul; 175():16-20. PubMed ID: 27131431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC; Kaufman HL
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies of antigen-specific T-cell-based immunotherapy for cancer.
    Liu SH; Zhang M; Zhang WG
    Cancer Biother Radiopharm; 2005 Oct; 20(5):491-501. PubMed ID: 16248765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stochastic modeling of tumor progression and immune evasion.
    George JT; Levine H
    J Theor Biol; 2018 Dec; 458():148-155. PubMed ID: 30218648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanisms of tumor escape from immunologic response].
    Costello RT; Gastaut JA; Olive D
    Rev Med Interne; 1999 Jul; 20(7):579-88. PubMed ID: 10434348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
    Knutson KL; Disis ML
    Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.